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Abstract 
Cell-bound lipases of dry mycelium of Aspergillus oryzae were used in organic solvent for the 
resolution of racemic flurbiprofen by direct esterification with ethanol in a flow-chemistry reactor. 
Under flow conditions a significant reduction of the reaction time and an increase of the 
enantioselectivity were achieved compared to the batch mode. Moreover, the process was 
implemented by adding an in-line purification step integrated with the racemization of the unreacted 
flurbiprofen directly into a polymer-supported resin. 
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Introduction  
Carboxylesterases (mostly lipases) have been used in monophasic organic solution under controlled 
values of water activity (aw) for catalyzing ester formation; the strategies more frequently employed 
for shifting the equilibrium towards ester formation imply the use of interesterification or 
transesterification, because direct esterification is often hampered by water formation, which 
negatively influences the equilibrium.1 The use of cell-bound enzymes of different microorganisms 
has proved an effective method for direct esterification of different alcohols and carboxylic acids in 
organic solvent.2 Dry whole mycelia of filamentous eumycetes can be directly used as biocatalyst, 
showing few advantages, such as: high stability in organic solvents, high resistance to the 
inactivation due to free carboxylic acids (including acetic acid) and high molar conversions enabled 
by favourable partition of water.3 Previous observations suggested that the mycelium contributes 
marginally to the water take-up: rather than sequestrating water inside the cell wall, it seems that the 
mycelium provides a micro-environment where the water produced during the esterification is 
promptly removed.4 Furthermore, mycelial microorganisms can be employed without 
immobilization, because their morphological structure allows for easy filtration and re-utilization; 
this last feature favours simple set-up of continuous bioreactors. 
Direct esterification of racemic alcohols or carboxylic acids with dry mycelia of strains of 
Aspergillus oryzae and Rhizopus oryzae often resulted in an efficient kinetic resolution.5 For 
example, Aspergillus oryzae has been used in pure organic solvent for the resolution of (RS)-
flurbiprofen,6 displaying good enantioselectivity towards (R)-flurbiprofen and furnishing results 
competitive with the data obtained using commercial enzymes.7 However, the biotransformations 
showed limited productivity and space time yield due to substrate inhibition effects and low 
solubility of flurbiprofen in the solvents where the best results, in terms of activity and 
enantioselectivity, were observed (e.g. aliphatic hydrocarbons).6 Kinetic resolution of racemic 
flurbiprofen is attractive because (S)-flurbiprofen is a non-steroidal anti-inflammatory drug, 
whereas its R-enantiomer shows anticancer effects in vivo and in vitro.8 Moreover, as recently 
reviewed by Kourist and co-workers,9 despite the considerable number of biocatalytic routes 
developed so far for the production of (S)-profens, there is still room for improvement with the 
perspective of more efficient and sustainable processes. 
Flow reactors can dramatically improve the performances of lipase-catalyzed reactions.10 Recently, 
the kinetic resolution of flurbiprofen has been performed in a continuous flow reactor using an 
immobilized lipase B from Candida antarctica (Novozym 435®) allowing a significant reduction of 
the reaction time compared to the classical batch method.11 
In the present work, we have studied the use of dry mycelium of Aspergillus oryzae12 in an organic 
solvent for the resolution of racemic flurbiprofen in a continuous flow reactor, combining the 
advantages of an easy to produce (and use) biocatalyst with a process-intensification technology. 
The process was implemented by adding an in-line purification step integrated with the 
racemization of the unreacted flurbiprofen directly into a polymer-supported resin. 
 
Results and discussion  
The esterification reaction catalyzed by dry mycelia of Aspergillus oryzae was firstly performed in a 
batch mode using stoichiometric amounts of racemic flurbiprofen and ethanol in n-heptane at 50 
°C.13 The progress and stereobias of the reaction was monitored by chiral HPLC,14 which showed 
that after 8 hours the enantiomeric excess of (S)-flurbiprofen 1 was 22%, the enantiomeric excess of 
the product (R)-flurbiprofen ethyl ester 2 was 86% and the conversion was 20%.  
Flow experiments were initially focused on reaching a degree of conversion similar to the one 
obtained in the batch process.15 To this aim, a 10 mM solution of (RS)-flurbiprofen 1 in n-heptane 
containing 1 equiv of EtOH was flowed through a glass column loaded with dry mycelium of 
Aspergillus oryzae MIM (180 mg, Scheme 1). Temperature was kept constant at 50 °C, while flow 
rate, which sets the residence time, was varied and the best results are reported in Table 1.16 
 
 
Scheme 1. Esterification of (RS)-flurbiprofen 1 with EtOH using mycelium of Aspergillus oryzae MIM in a continuous flow reactor. 
 
Table 1. Screening of different flow rates in the enantioselective esterification of (RS)-flurbiprofen 1 with EtOH using 
Aspergillus oryzae MIM in a continuous flow reactor. 
Entry Time (min) Flow rate (µl/min) Molar conversion (%)a ees(%)b eep(%)b Ea r (µmol/min g)c 
Batch 1440 - 20 22 86 16 0.14 
1 15  46 58 90 66 18 1.48 
2 8  85 45 66 82 19 2.12 
3 6.5  105 28 34 88 21 1.63 
4 5 137 19 20 88 19 1.44 
Reaction conditions: 10 mM solution of (RS)-flurbiprofen in n-heptane, 1 equiv of EtOH, 180 mg of lyophilized mycelium of Aspergillus oryzae 
MIM, T = 50 °C. aCalculated according to Ref. 17. bDetermined by chiral HPLC.14 cCalculated according to Ref. 18. 
 
The data reported in Table 1 indicate that the use of a flow reactor dramatically reduced the reaction 
time and slightly increased the enantioselectivity. In fact, a 19% conversion was reached in only 5 
min of residence time with 88% enantiomeric excess (ee) of the product (Table 1, entry 4). On the 
other hand, a residence time of 15 min (entry 1) resulted in a marked increase of the conversion 
(58%) allowing, in this case, the obtainment of (S)-flurbiprofen with a good enantiomeric excess 
(90% ee). Therefore, by simply modulating the flow rate, optically enriched substrate [(S)-
flurbiprofen, entry 1] or product [(R)-flurbiprofen ethyl ester, entries 3 and 4] could be obtained.  
The specific reaction rate (r) of the batch reaction was 0.14 µmol/min g, whereas in the flow 
process, using the conditions reported in Table 1, entry 4, which provided a similar degree of 
conversion of the batch reaction, the specific reaction rate was 1.44 µmol/min g, that means an 
increase of the productivity of about 10 times. It must be noted that the resolution is obtained 
through direct esterification with formation of water, which can affect the equilibrium of the 
reaction and, consequently, the overall stereoselectivity. Therefore, experiments in presence of 
molecular sieves were carried out. For this purpose, we prepared a mixed bed column filled with an 
equal weight of lyophilized mycelium of Aspergillus oryzae MIM and molecular sieves. Keeping 
constant the temperature and the residence time at 6.5 min, it was possible to observe an increase of 
the molar conversion from 28% (Table 1, entry 3) to 38%(Table 2, entry 1). Different temperatures 
were then tested (Table 2, entries 2-5). A slight increase of both the molar conversion and ee of the 
product was achieved working at 60 °C (Table 2, entry 4). No significant differences in the 
conversion or in the ee of the product were observed by increasing the equivalents of EtOH. 
 
Table 2. Screening of different temperatures in the enantioselective esterification of (RS)-flurbiprofen with EtOH using 
Aspergillus oryzae MIM in presence of molecular sieves in a continuous flow reactor. 
Entry T (°C) Molar conversion (%)a ees(%)b eep(%)b Ea r (µmol/min g)c 
1 50 38 54 88 26 2.45 
2 30 30 38 88 22 1.93 
3 40 32 42 88 23 2.06 
4 60 41 62 90 35 2.64 
5 70 42 60 84 21 2.70 
Reaction conditions: 10 mM solution of (RS)-flurbiprofen in n-heptane, 1 equiv of EtOH, 180 mg of lyophilized mycelium of Aspergillus oryzae 
MIM and 180 mg of molecular sieves (powder, 4 Å). Residence time: 6.5 min; flow rate 116 µL/min. aCalculated according to Ref. 17. bDetermined 
by chiral HPLC.14 cCalculated according to Ref. 18. 
 
The addition of molecular sieves generally increased the specific reaction rates and 
enantioselectivity; under the best conditions (Table 2, entry 4), the specific rate was 19 times higher 
than the one registered in the batch mode and the enantiomeric ratio (E) was increased from 16 to 
35.  
Moreover, the stability of the lyophilized mycelia was evaluated. The thermal stability was already 
demonstrated by us in a previous work,3a whereas the mycelia stability over continuous work was 
checked by performing the resolution under the conditions reported in table 2, entry 4, and running 
the reactor for 3 hours. Samples were collected and analyzed every hour and it was verified the 
matching of the results obtained both in term of conversion and enantiomeric purity of substrate and 
product. 
As previously described,11 the overall process can be implemented by adding an in-line purification 
step of the exiting solution, consisting in a catch and release protocol, which allows the easy 
separation and recovery of both (S)-flurbiprofen and (R)-flurbiprofen ethyl ester. Following the 
reported procedure, the unreacted carboxylic acid was trapped by flowing the exiting solution into a 
column containing the polymer-supported base Amberlyst A21 (Scheme 2). To further improve the 
process, the racemization of the trapped (S)-flurbiprofen 1 was included. The complete racemization 
was achieved by filling the column with a 10% solution of DBU in n-heptane (prepared through 
dilution of the DBU charged in one injection loop with the n-heptane flow stream) and, after 
stopping the flow stream, heating the column at 115 °C for 1 h. Lower concentration of DBU did 
not allow the complete racemization of the trapped acid. The column was then washed with n-
heptane for 10 min at a total flow rate of 300 µL/min, and subsequently, flurbiprofen was released 
with a 5% solution of AcOH in n-heptane and analyzed by chiral HPLC. 
 
 
Scheme 2. Schematic representation of the overall process. 
 
Conclusion 
Dry mycelia of Aspergillus oryzae can be effectively used for enantioselective esterification of 
racemic flurbiprofen in organic solvent in a flow reactor. The procedure here reported appears to be 
notably simple because dry mycelium can be directly used in the continuous reactor without 
immobilization. To the best of our knowledge, this is the first application of microbial whole cells 
as an enantioselective biocatalyst in a continuous flow reactor. Moreover, as previously observed in 
the kinetic resolution of flurbiprofen using of a commercially available immobilized lipase B from 
Candida antarctica,11 the use of a continuous flow reactor allows a significant reduction of the 
reaction time compared to the classical batch method and dramatically improved the productivity of 
the batch biotransformation, with beneficial effects also on the enantioselectivity.  
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